Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder...
Exhibit 10.1
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the xxxx “[***]”.
AMENDMENT NO. AR3 TO
AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT
This Amendment No. AR3 to the Amended and Restated Collaboration and License Agreement (the “Amendment No. AR3”), effective as of January 27, 2022 (the “Amendment No. AR3 Effective Date”), is by and between X. X. Xxxx Research, LLC, a Delaware limited liability company located at 000 Xxxx 00xx Xxxxxx, 00xx Xxxxx, Xxx Xxxx, XX 00000 (“DESRES”), and Relay Therapeutics, Inc., a Delaware corporation located at 000 Xxxxxx Xxxxxx, Xxxxxxxxx, XX 00000 (“Company”). DESRES and Company are each sometimes referred to herein as a “Party” or collectively as the “Parties”.
WHEREAS, DESRES and Company are parties to the Amended and Restated Collaboration and License Agreement, effective as of June 15, 2020, as amended by Amendment No. AR1 effective as of February 4, 2021, and by Amendment No. AR2 effective as of May 12, 2021 (collectively, the “Agreement”);
WHEREAS, the Parties desire to re-categorize certain Targets by mutual agreement, as set forth below;
NOW THEREFORE, the Parties agree, in accordance with Section 17.4 of the Agreement, as follows:
1.1 pursuant to Section 4.7(e) of the Agreement, the following Targets, which, prior to the Amendment No. AR3 Effective Date, had been Category 3 Targets, shall be Category [***] Targets:
[***]
1.2 pursuant to Section 4.7(e) of the Agreement, the following Targets, which, prior to the Amendment No. AR3 Effective Date, had been Category 3 Targets, shall be Category [***] Targets:
[***]
1
1.3 pursuant to Section 4.7(d) of the Agreement, the following Targets, which, prior to the Amendment No. AR3 Effective Date, had been Category 2 Targets, shall be Category 3 Targets:
[***]
[Signature Page Follows]
2
IN WITNESS WHEREOF, the Parties have caused this Amendment No. AR3 to be executed by their duly authorized representatives.
X. X. Xxxx Research, LLC |
|
By: /s/ Xxxxxxxx XxXxxxx |
By: /s/ Xxxxx Xxxxx |
Name: Xxxxxxxx XxXxxxx |
Name: Xxxxx Xxxxx |
Title: Authorized Signatory |
Title: Chief Legal Officer |
3
Exhibit A-1: Category 1 Targets
(on and after the Amendment No. AR3 Effective Date)
[***]
4
Exhibit A-2: Category 2 Targets
(on and after the Amendment No. AR3 Effective Date)
[***]
5